Postinfarction left ventricular remodelling: Where are the theories and trials leading us?

Heart

Volumn 83, Issue 1, 2000, Pages 76-80

  Yousef, Z R ^a   Redwood, S R ^a   Marber, M S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ARTERY WALL; BLOOD VESSEL DIAMETER; HEART VENTRICLE REMODELING; HUMAN; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0034108080     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.83.1.76     Document Type: Review

References (40)

1. 1 Garg R, Packer M, Pitt B, et al. Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol 1993;22(suppl A):3-5A.
2. 2 Mahon NG, O'Roke C, Codd MB, et al. Hospital mortality of acute myocardial infarction in the thrombolytic era. Heart 1999;81:478-82.
3. 3 Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36.
4. 4 Habib GB, Heibig J, Forman SA, et al. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. Circulation 1991;83:739-46.
5. 5 The ISIS-2 collaborative group. Second International Study of Infarct Survival. Lancet 1988;ii:349-60.
6. 6 Braunwald E, Pfeffer M.A. Ventricular enlargement and remodelling following acute myocardial infarction: mechanisms and management. Am J Cardiol 1991;68(suppl D):1-6D.
7. 7 Stillwell GK. The Law of Laplace. Some clinical applications. Mayo Clin Proc 1973;48:863-9.
8. 8 White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76:44-51.
9. 9 Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995;27:1281-92.
10. 10 Hirohata S, Kusachi S, Murakami M, et al. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 1997;78:278-84.
11. 11 Olivetti G, Capasso JM, Sonnenblick EH, et al. Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res 1990;67:23-34.
12. 12 McAlpine HM, Morton JJ, Leckie B, et al. Neuroendocrine activation after acute myocardial infarction. Br Heart J 1988;60:117-24.
13. 13 Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54,
14. 14 Sugden PH. Signalling in myocardial hypertrophy - life after calcineurin? Circ Res 1999;84:633-46.
15. 15 Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
16. 16 Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
17. 17 CIBIS-II Investigators and Committees. The Cardiac Insufficiency Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
18. 18 GISSI-3: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
19. 19 Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
20. 20 The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
21. 21 Goodfriend TL, Elliot ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.
22. 22 Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
23. 23 Struthers AD. Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? BMJ 1994;308:1615-19.
24. 24 Lang CC, Struthers AD. Atrial and brain natriuretic peptides - a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin Sci 1992;83:519-27.
25. 25 Trippodo NC, Fox M, Monticello TM, et al. Simultaneous inhibition of neutral endopeptidase and angiotensin converting enzyme by omapatrilat increased survival in heart failure hamsters greater than with ACE inhibition. Circulation 1998;98(suppl I):4095.
26. 26 Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
27. 27 Watanabe T, Suzuki N, Shimamoto N, et al. Endothelin in myocardial infarction. Nature 1990;344:114.
28. 28 Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997;96:1976-82.
29. 29 Packer M, Caspi A, Charlon V, et al. Multi-centre, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure - results of the REACH-1 trial. Circulation 1998;98(suppl I):12.
30. 30 Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997;80(suppl A):15-25L.
31. 31 Simpson PC. Role of proto-oncogenes in myocardial hypertrophy. Am J Cardiol 1988;62(suppl G):13-19G.
32. 32 Iwaki K, Sukhatme VP, Shubeita HE, et al. α-and β-adrenergic stimulation induces distinct patterns of immediate gene expression in neonatal rat myocardial cells. J Biol Chem 1990;265:13809-17.
33. 33 Adinolfi A, Adinolfi M, Lessof MH. Alpha-feto-protein during development and in disease. J Med Gen 1975;12:138-51.
34. 34 Vannan MA, Taylor DJ. Ventricular remodelling after myocardial infarction. Br Heart J 1992;68:257-9.
35. 35 Marber MS, Brown DL, Kloner RA. The open artery hypothesis: to open, or not to open, that is the question. Eur Heart J 1996;17:505-9.
36. 36 Hochman JS, Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 1987;75:299-306.
37. 37 White HD, Cross DB, Elliot JM, et al. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994;89:61-7.
38. 38 The SWIFT investigators (Should We Intervene Following Thrombolysis?). SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. BMJ 1991;302: 555-60.
39. 39 Williams DO, Braunwald E, Knatterud GK, et al. One-year results of the thrombolysis in myocardial infarction investigation (TIMI) phase II trial. Circulation 1992;85:533-42.
40. 40 Horie H, Takahashi M, Minai K, et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation 1998;98:2377-82.